Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embla Medical hfOCSE:EMBLA +0.73%92 EBITDA Margin % is 23.13% as of Jun. 2026, which is 21% above its 10-year median of 19.09. GuruFocus rates OCSE:EMBLA with a GF Score™ of 92/100 and a GF Value™ of kr34.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, Embla Medical hf ranks better than 77.06% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Embla Medical hf's EBITDA for the
three
months ended in Jun. 2026 was kr388 Mil. Embla Medical hf's Revenue for the
three
months ended in Jun. 2026 was kr1,678 Mil. Therefore, Embla Medical hf's EBITDA margin for the quarter that ended in Jun. 2026 was 23.13%.
Embla Medical hf (OCSE:EMBLA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Embla Medical hf EBITDA Margin % Related Terms
Embla Medical hf EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:EMBLA vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Embla Medical hf's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf (OCSE:EMBLA) has a EBITDA Margin % of 23.13% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Embla Medical hf and its competitors. This is 21% above median its historical median of 19.09. Over the past decade, Embla Medical hf's EBITDA Margin % has ranged from 13.83 to 21.06. According to the industry distribution chart, Embla Medical hf ranks #187 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 22.9%.
Is Embla Medical hf's EBITDA Margin % too high?
Embla Medical hf's current EBITDA Margin % of 23.13% is 21% above median its 10-year median of 19.09. Over the past 10 years, this metric has ranged from a low of 13.83 to a high of 21.06. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Embla Medical hf's value of 23.13% is 209.6% above this industry median. Based on the distribution chart, Embla Medical hf ranks #187 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Embla Medical hf has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #187 out of 815 companies for EBITDA Margin %. This places Embla Medical hf in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Embla Medical hf's value of 23.13% is 209.6% above this benchmark. Historically, Embla Medical hf's own EBITDA Margin % has ranged from 13.83 to 21.06 over the past decade. While the company's 10-year median is 19.09 vs. the industry median of 7.47, Embla Medical hf has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current EBITDA Margin % of 23.13% is 209.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current EBITDA Margin % is 23.13%, which is 21% above median its own 10-year median of 19.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OCSE:EMBLA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.09, compared to a current price of kr27.45 — trading 19.5% below its estimated fair value. The current EBITDA Margin % is 23.13%, which is 21% above median its 10-year median of 19.09 and 209.6% above the Medical Devices & Instruments industry median of 7.47. Embla Medical hf's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Embla Medical hf (OCSE:EMBLA), the current EBITDA Margin % is 23.13% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of kr27.45 is trading 19.5% below its estimated GF Value™ of kr34.09.
GuruFocus considers Embla Medical hf to be Modestly Undervalued.
Key valuation signals for OCSE:EMBLA:
EBITDA Margin %: 23.13% (21% above median its 10-year median of 19.09)
GF Value™: kr34.09 vs. price of kr27.45 (19.5% below fair value)
Industry Position: 209.6% above the Medical Devices & Instruments median (#187 of 815)
No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OCSE:EMBLA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:EMBLA has been successfully added to your 
